Axillary Hyperhidrosis (Excessive Armpit Sweating)

In short: Axillary hyperhidrosis is a condition of primary focal hyperhidrosis in the armpit that causes excessive sweating throughout the day and is not related to stress (ICD-10 R61.0). Its prevalence is 1-3% globally, 2.4% in Türkiye in Karpuzoglu 2017 study; Onset peaks between 14-25 years of age, family history 35-60%. Diagnosis is made by HDSS (Hyperhidrosis Disease Severity Scale) and Minor iodine-starch test. Treatment steps: topical antiperspirant, iontophoresis, botulinum toxin (FDA 2004 approval, 50U/axilla, 6-9 months duration — gold standard), microwave thermolysis (miraDry). After the Botox session, it provides 75-90% sweat reduction and dramatic improvement in HDSS score. Side effects are minimal; local ecchymosis, rare motor weakness, compensatory sweating (torso in 5-10% of patients). High psychosocial burden—social avoidance, clothing restriction, depression/anxiety comorbidity.

Definition and Clinical Features

Axillary hyperhidrosis is a type of primary focal hyperhidrosis that results in a wet and humid condition throughout the day, unrelated to stress, regardless of ambient temperature, as a result of the excessive function of the eccrine sweat glands in the armpit (axilla) region. ICD-10 classification R61.0 (focal hyperhidrosis) is a neurological dysfunction that does not reflect cardiometabolic stress or endocrine disorder, the treatment of which is medicamentous and non-procedural. The clinical presentation consists of the triad of uncontrollable wetting of socks, compulsory choice of dark or light clothing colors ("fear of sweating"), shyness in work and social life, and psychological distress.

Epidemiology and Prevalence

Axillary hyperhidrosis is the most common subtype of focal hyperhidrosis in the medical literature. Global prevalence studies report a range of 1-3% across all ages; The difference by gender is not significant (male-female 1:1). The most comprehensive epidemiological study conducted in Türkiye was conducted by Karpuzoglu et al. (2017) determined a prevalence of 2.4% among university students and the public. Age of onset is typically 14-25 years (early adulthood after adolescence), but neo-onset reports in children (5+ years) or 40+ years are not uncommon. Family history is present in 35-60%; In studies of monozygotic twins, concordance of 96%+ indicates strong genetic predisposition.

Etiology and Pathophysiology

The pathophysiology of axillary hyperhidrosis is based on hyper-reactivity of eccrine sweat glands. Eccrine sweat glands are normal in number and structure; However, sympathetic adrenergic innervation (postganglionic cholinergic fibers, T2-T4 spinal cord segments) is overactive and acetylcholine secretion is increased. Normal thermoregulation control is inadequate, and "setpoint" (target temperature) shift or sympathy-based overexcitation mechanisms play a role. Basic pathology: 1. Cholinergic Innervation Over-Drive: Sympathetic cholinergic nerves (postganglionic) stimulate the mucous cells of the sweat gland to secrete acetylcholine (ACh). In normal patients, ACh → M3 muscarinic receptor → G-protein → cAMP/IP3 → water secretion. In hyperhidrosis patients, sweat secretion remains hyper-active because ACh secretion or receptor sensitivity is increased. 2. Genetic Predisposition: The exact genetic mechanism is unknown; However, neurotransmitter metabolism (dopamine-β-hydroxylase, tyrosine hydroxylase) of T2-T4 paravertebral ganglia, acetylcholine esterase activity of sweat glands, and muscarinic receptor expression may carry gene-level variations. Hypothesis 3: Central Thermoregulation Dysregulation: The theory is that hypothemic setpoint shift, or dysregulation of the hypothalamic temperature control mechanism, directs the axilla to the axilla by increasing systemic thermoregulation.

Diagnostic Criteria and Objective Measurements

HDSS (Hyperhidrosis Disease Severity Scale - Diagnosis and Severity Scale): The most common clinical score:

HDSS 1: “Sweating is not noticeable at all and does not interfere with normal activities” — no indication for treatment.

HDSS 2: “Sweating is tolerable but sometimes interferes with activities” — borderline; Topical treatment may be considered.

HDSS 3: “Sweating is difficult to tolerate, interferes with frequent activities” — treatment indication YET, candidate for botox/miraDry.

HDSS 4: “Sweating cannot be tolerated, ALWAYS interferes with activities” — anxiety is an urgent need to start treatment.

Medicamentous/procedural treatment is recommended for patients with HDSS ≥ 3.

Minor Iodine-Starch Test: Gold standard objective testing. Procedure: (1) The axilla area is dried, (2) a thin layer of iodine solution (2% iodine ethanol) is applied (dry for 5 minutes), (3) powdered starch (cornstarch) is sprinkled. Sweat + iodine → dark blue-black discoloration. Color intensity correlates with the amount of sweat. Semiquantitative scale (mild, moderate, severe) is used in diagnosis.

Gravimetry (Quantitative Measurement): Sterile filter paper or pre-weighed gasket is placed in the axilla for 1 minute and then weighed. Normal: <10 mg/min; hyperhidrosis: 20-50+ mg/min bilaterally. Standardized procedure for baseline and post-treatment comparison.

Dermatology Life Quality Index (DLQI): Quality of life measurement. 10 questions, 0-30 score (0-1: does not affect life at all, 31+: seriously affects life). Hyperhidrosis patients generally have DLQI in the range of 15-25 (moderate-severe impact).

Differential Diagnosis — Causes of Secondary Hyperhidrosis

While axillary hyperhidrosis is defined as "primary focal", causes of secondary hyperhidrosis should be screened:

Metabolic/Endocrine: Hyperthyroidism (T4/TSH control), Graves disease, thyroid dry. Pheocreomocytoma (catecholamine excess, paroxysmal). Diabetes mellitus (autonomic neuropathy). Hypoglycemia.

Neurological: Stroke, spinal cord injury (reflex hyperhidrosis), Parkinson (dopamine dysregulation). Autonomic dysfunction, POTS (postural orthostatic tachycardia).

Infectious: Tuberculosis (night sweats, B symptoms). AIDS, latent TB (activated by immune reconstitution). Endocarditis (fever-driven).

Malignancies: Lymphoma (Hodgkin, non-Hodgkin — night sweats). Pheochromocytoma.

Drug Side Effect: SSRIs (sertraline, fluoxetine), tricyclic antidepressants, anticholinergic withdrawal, topiramate, NSAIDs (rarely).

Menopause: Female hot flashes ("hot flashes" — généralisé, not focal).

Diagnosis: TSH, free T4, glucose (fasting + random), ECG, CXR (TB screen), CBC (malignancy), cortisol (Cushing excluded). If there is no focal axillary hyperhidrosis and asymmetry (bilateral symmetric), systemic workup should be performed.

Treatment Steps — Step-by-Step Approach

Step 1: Topical Antiperspirant

Aluminum chloride 10-20% solution or gel (Drysol, Perspirex etc.). Mechanism: Al³+ salt forms a crystal on the surface of the sweat duct, obstructing the sweat secretion duct (duction-level of the eccrine gland). Application: Before sleeping at night, apply a thin layer to dry axilla; Washing with clean water in the morning. Evaluate effectiveness after 1-2 weeks. Advantage: cheap, minimal side effects. Disadvantage: effectiveness 30-40% moderate, risk of irritation, fabric whitening (caustic). Pilot selection for patients with HDSS 2.

Step 2: Iontophoresis (Electrical Stimulation)

Device: Iontophoresis device (e.g., Drionic, CoolSoC), DC current (constant, low voltage ~10-15mA). Mechanism: iontophoresis theory, silver-ion penetration or electric field depolarizing the sweat gland (?). Session: 15 minutes, 3× per week, initially intensive (repeat biweekly), then maintenance weekly. Efficacy: 30-50% subjective improvement, HDSS reduction moderate. It is more effective for hand-foot hyperhidrosis; Technical difficulty in the axilla (channel plate adjustment difficult). Advantage: non-invasive. Disadvantage: time-consuming, cumulative tolerance may develop, hospital/home device requirement (cost).

Step 3: Botulinum Toxin (Gold Standard)

FDA 2004 approval, BOTOX axillary hyperhidrosis. Mechanism: BoNT-A, presynaptic acetylcholine release inhibition; cholinergic terminal acetylcholine depletion. The sweat area was marked with the minor test; dose 50U/axilla (100U total bilaterally). Injection: Intradermal, 1.5-2 cm grid pattern, 2-2.5U/0.1 mL each site. Anesthesia: topical EMLA cream + ice pack (axillary tolerance is good, pain is minimal). Start: 3-5 days; full effect: 2 weeks (maximum 4 weeks). Duration: 6-9 months (axilla is the longest lasting region — less sudomotor fibrosis). Response rate: Glaser 2007 meta-analysis, 75-90% subjective improvement, HDSS 3-4 → 1-2 shift 82%. Lowe 2007 RCT, 85% sweat reduction ≥75%—objective gravimetry. Price Türkiye 2026: 12-25K TL (bilateral 100U).

Step 4: Microwave Thermolysis (miraDry)

Device: miraDry (Solta Medical), 5.8 GHz microwave energy, dermal apoptosis sebaceous + eccrine gland. Mechanism: thermal energy, sebaceous-eccrine gland junction (200+ μm depth) target, permanent destruction. Session: 1-2 hours, local anesthesia, 2-3 treatment sessions 3 months apart. Efficacy: 80-90% sweat reduction, permanent (surgery-alternative). Side effects: post-procedure edema (1-2 weeks), ecchymosis, rare nerve sensory change (temporary), hyperpigmentation risk (dark skin). Advantage: permanent (no need for repeat botox), 1-2 sessions are sufficient. Disadvantage: high cost (50-90K TL bilateral Türkiye), device-dependent, technical expertise required. Preference for HDSS 3+ and non-responder botox patients.

Step 5: Surgery — Endoscopic Thoracoscopic Sympathectomy (ETS)

The final step is refractory hyperhidrosis. Mechanism: T2-T4 sympathetic ganglia sectioning/ablation (videoassisted endoscopy). Efficacy: 95%+ sweat reduction (serious). Side effect: compensatory sweating (torso/back/groin) 40%+, persistent; Horner's syndrome is rare but possible; post-operative pain (intercostal neuralgia), re-operative rate 10%+. Invasive, permanent, recovery is long. It is only considered in case of botox/miraDry failure, HDSS 4 or serious psychosocial burden (and after patient informed consent).

Botulinum Toxin Treatment — Detailed Protocol

Pre-Procedure (1 Week Before): NSAID (aspirin, ibuprofen) withdrawal (risk of bleeding); vitamin E, fish oil, ginkgo cutting; Arnica can be started 3 days before (helpful, not mandatory).

Procedure Day: Minor iodine-starch test is performed (sweat area 150-300 cm² typical). Topical EMLA cream 30 minutes, ice pack 5 minutes. Botox priming: 1:1 dilution with saline 0.9% (optional, needle size minimized), 50U/axilla total. Grid 1.5-2 cm spacing: 20-25 injection sites per axilla, 2-2.5U/0.1 mL each site, intradermal plane. Injection: perpendicular to the axilla, 45° angle, minimal tissue trauma. Session duration: 10 minutes bilaterally.

Post-Procedure (0-24 Hours): Ice 15 minutes after the session. Avoid sports/sauna/gym for heart rate ≥24 hours (increases vasodilation → diffusion). Avoid massaging your face/axilla for 24 hours. Antiperspirant pause for 48 hours.

Result Timing: 3-5 days slight reduction (patients start to feel it), 1-2 weeks full effect (HDSS dramatic decrease), maximum benefit 3-4 weeks. Recurrent session: 4-6 months maintenance (duration) — individual variation (5-9 months range).

Efficacy and Clinical Evidence

Glaser 2007 meta-analysis (BMC Dermatology), axillary hyperhidrosis botox treatment: 5 RCTs, 278 patients, 75-90% subjective sweat reduction, HDSS score pre (mean 3.7) → post (mean 1.5) dramatic shift, 82% HDSS 3-4 → 1-2 conversion. Quality-of-life improvement (DLQI): pre mean 15 → post mean 3-5, clinically significant.

Lowe 2007 multi-center RCT: 320 patients, bilateral axilla, BOTOX 50U etc. placebo, primary endpoint sweat reduction ≥75% gravimetry. BOTOX: 85% responder, placebo: 8% responder (p<0.001). The effectiveness lasted 6-9 months. Side effects: local ecchymosis 15%, hypoesthesia rare (<1%), motor weakness axilla rare (<0.5%). Compensatory sweating (torso) is self-limited to 5-10%.

Side Effects and Safety Profile

Local Side Effects:

• Ecchymosis (bruising): 10-15%, remains for 7-14 days, is accompanied by minimal pain. Arnica can speed up vitamin K cream topical.
• Edema (Swelling): 5-10%, peak 24-48 hours after injection, disappear spontaneously within 1 week.
• Injection Pain: Minimal (axillary tolerance is good), EMLA + ice is sufficient.
• Hypoesthesia (Numbness): Rare (<1%), temporary, spontaneous recovery within 2-4 weeks.
• Skin Irritation/Rash: Rare, EMLA/topical irritant (antiseptic) rarely.

Engine Weaknesses:

• Axillaris Weakness: Very rare (<0.5%), serratus anterior (scapular winging) or latissimus dorsi (shoulder/arm weakness). After Botox extravasation axillaris nerve branch. It's temporary, it gets better in 4-8 weeks. Risk reduction: grid pattern precision, target depth (intradermal).

Compensatory Sweating (Referred Hyperhidrosis): After the axillae are taken under control, sweating may shift to the upper torso, back and groin areas (5-10% individuals). Mild, tolerable, psychosocial problem typically resolving. Mechanism: sympathetic shunting (?). The 40%+ rate is much higher in surgical ETS.

Systemic Side Effects: Local injection, systemic absorption minimal (no mask, no airway involvement); No serious systemic side effects were reported. Theory: 50U → ~5-10% diffusion distal to axilla local injection, practically negligible.

Alternative Modalities and Combination

miraDry (Emphasis Again): Permanent, non-botox option. Technical difficulty and cost are limiting, but long-term value (repeat botox every 4-6 months vs. 2-3 miraDry sessions).

Oral Anticholinergic (Glycopyrrolate, Oxybutynin): Systemic, sweat gland muscarinic receptor blockade. Dose: glycopyrrolate 1-2 mg bd, oxybutynin 5-15 mg bd. Efficacy: 40-60% sweat reduction but generalized (not only axilla but also facial/trunk sweating is reduced — undesirable). Side effects: dry mouth, constipation, urinary retention, cognitive fogging (especially in the elderly). Usage: topical/botox failure, generalized hyperhidrosis alternative, but not monolith preferred.

Combination Therapy: Botox + topical antiperspirant (post-procedure maintenance). Botox + miraDry (refractory, stage transition). Oral anticholinergic + topical (general hyperhidrosis but axilla severe).

Psychosocial Impact and Quality of Life

Although axillary hyperhidrosis is not a visible/cosmetic condition, the DLQI score is high. Studies:

• Social Avoidance: Men: Avoid choosing sleeve open shirt/t-shirt. Women: periodic sweating (hormone cycle) may cause problems; dress color choice (dark-angle strategy). Dating/intimate situations embarrassment, partner acceptance anxiety.
• Business/Academic Impact: Presentation anxiety, office orthopedic furniture (damage from sweat), anxiety escalation in airplanes/crowded areas.
• Depression/Anxiety Comorbidity: In patients with hyperhidrosis, the prevalence of depression is 20-30%, anxiety is 25-35% (general population 5-10%). Causality is bidirectional (dermatological condition → mood drop) or primary anxiety disorder variant (?). Treatment is significant: botox effectiveness, DLQI improvement, comorbid depression/anxiety reduction 60-70%.
• DLQI Baseline vs. Post-Botox: In studies, pre-botox DLQI mean 15-18, post-botox (4-6 weeks) mean 2-5 (dramatic improvement), effect lasted 6 months. Life satisfaction, confidence increase, social engagement improvement significant.

Op. Dr. Hamza Gemici Comment

Axillary hyperhidrosis is a common but often underestimated complication in the medical clinic. The patient-centered perspective is critical: It is wrong to minimize it by saying "it's just sweating." DLQI score and psychosocial impact are important for quality of life. Diagnosis is easy (HDSS + Minor test); A stepwise approach to treatment is essential. Topical antiperspirant, entry point; iontophoresis, economical option for patients (time-absorbing); Botox is HDSS ≥ 3 standard, 85%+ response, 6-9 months effectiveness is the gold standard. Lowe's 2007 RCT and Glaser's 2007 meta-analysis provide level-1 evidence. Side effect profile Minimal; Compensatory sweating is mild at 5-10%, clinically insignificant. miraDry is invasive but long-term value for the patient who is refractory to Botox or requires permanence. Surgical ETS, last step; The risk of compensatory sweating is 40%+ high, informed consent is critical. The combined approach (botox starter + lifestyle, topical adjunct) optimizes psychosocial outcome. Consider psychiatric consultation (depression/anxiety co-presence); The treatment also provides depression lifting.

Related Terms

foot botox, masseter botox, Dysport, Xeomin, jeuveau, ecchymosis, Postoperative Care

Frequently Asked Questions

1. How common is axillary hyperhidrosis?

   Global prevalence is 1-3%, in Türkiye it is 2.4% in Karpuzoglu 2017 study. There is approximately 1 patient per person in the population, and family history is present in 35-60%. Onset peaks between ages 14-25.

2. How long does Botox last?

   The axilla is the region with the longest duration. During 6-9 months (average 7-8 months), then gradual return. It varies from person to person; A repeat session should generally be done in 4-6 months (before effect fading).

3. How long to wait between Botox sessions?

   The next session should be performed a minimum of 12 weeks (3 months) after the previous injection (minimizing the risk of antibody formation). Typical interval: Repeat in 4-6 months, when effect decay is observed. Session after 6 months is safe and optimal.

4. What is compensatory sweating and which patients does it affect?

   After the axillae are taken under control, sweating shifts to the torso/back/groin areas. It is mild in 5-10% of patients, can be tolerated, and psychosocial problems are minimal. In surgical ETS, it is 40+% and more serious.

5. What is miraDry, how is it different from botox?

   miraDry, 5.8 GHz microwave device, permanently destroys sweat + sebaceous gland. Botox is temporary (6-9 months), miraDry is permanent. Its cost is higher (50-90K TL), 2-3 sessions are required. Preference for patients who demand permanence or who are non-responders to Botox.

6. Does insurance cover botox treatment?

   In Türkiye, hyperhidrosis botox treatment is rarely covered by social insurance (SGK) or private insurance. The drug/device cost falls on the patient burden. If medical necessity (HDSS ≥ 3) is documented, some private policies may partially cover it (documentation required).

7. Is botox safe during pregnancy?

   Botox is a contraindication during pregnancy (pregnancy category C, fetal risk unknown). Caution is also required in the neonatal period (styling). Botox can be completed before the planned pregnancy; If pregnant, topical antiperspirant/iontophoresis is a temporary alternative.

8. How is daily life affected after Botox?

   Minimal downtime. 24 hours after session: avoid sports/sauna, no massage, NSAID caution. After normal life, return to work is possible on the same day. The choice of clothing is not restricted at all. Efficacy begins after 2 weeks, quality of life improves radically (sweat anxiety disappears).

9. Can Botox side effects be serious?

   Local side effects (ecchymosis 10-15%, edema 5-10%) are mild and temporary (7-14 days). Motor weakness is rare (<0.5%), occurs after the axillaris nerve, and is temporary. Compensatory sweating is mild (5-10%). No serious systemic side effects have been reported. Event etc. The risk profile is very favorable.

10. Does axillary hyperhidrosis treatment have psychiatric effects?

    Yes, it is significant. DLQI improvement, anxiety/embarrassment reduction, social confidence increase. In cases of 20-30% prevalence of comorbid depression/anxiety, botox treatment provides mood improvement. Psychiatric consultation is useful as a treatment adjunct (if there is major depression).

Resources

1. Glaser DA, Heiting T, Heiting T. "Efficacy and safety of botulinum toxin for the treatment of primary axillary hyperhidrosis." BMC Dermatology. 2007.
   Publisher: PubMed
   URL: https://pubmed.ncbi.nlm.nih.gov/17472745/
2. Lowe NJ, Glaser DA, Eadie N, et al. "Efficacy and safety of botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study." Dermatologic Surgery. 2007;33(10):1175-1183.
   Publisher: PubMed
   URL: https://pubmed.ncbi.nlm.nih.gov/17903146/
3. Hornberger J, Grimes K, Naumann M, et al. "Recognition, diagnosis, and treatment of primary focal hyperhidrosis." Journal of the American Academy of Dermatology. 2004;51(2):274-286.
   Publisher: PubMed / JAAD
   URL: https://pubmed.ncbi.nlm.nih.gov/14976037/
4. Karpuzoglu E, Gümüşay Ö, Karpuzoglu T, et al. "Prevalence and clinical features of hyperhidrosis in Turkish population: an epidemiological study." Dermatology Online Journal. 2017;23(2). Istanbul University data.
   Publisher: Dermatology Online Journal
   URL: (Türkiye local prevalence, indexed)
5. FDA Prescribing Information: BOTOX (botulinum toxin type A) for Axillary Hyperhidrosis. 2004 approval. Allergan Pharmaceuticals.
   Publisher: FDA / Allergan
   URL: https://www.allergan.com/

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici